New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate 98.3845%; barium sulfate 98.453%{relative} (88.6272% barium sulfate 10µm + 9.8258% w/w barium sulfate 1µm) - powder for oral suspension - 98.38% w/w - active: barium sulfate 98.3845% excipient: citric acid monohydrate ethyl maltol strawberry natural and artificial 244259 polyoxyethylene glyceryl mono-oleate saccharin sodium simeticone sodium carrageenan sodium citrate dihydrate sorbitol vanilla active: barium sulfate 98.453%{relative} (88.6272% barium sulfate 10µm + 9.8258% w/w barium sulfate 1µm) excipient: acacia carrageenan citric acid ethyl maltol natural and artificial cherry flavour 308414 artificial strawberry flavour 308415 polysorbate 80 saccharin sodium simeticone sodium citrate dihydrate sorbitol

Malta - English - Medicines Authority

sanochemia diagnostics deutschland gmbh stresemannallee 4c, d-41460 neuss, germany - barium sulfate - powder for oral suspension - barium sulfate 96.805 % (w/w) - contrast media

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco imaging spa - barium sulfate - powder for oral suspension - 98.45%w/w percent weight/weight - barium sulfate containing x-ray contrast media; barium sulfate with suspending agents

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco imaging spa - barium sulfate - powder for rectal suspension - 96.5 percent weight/weight - barium sulfate containing x-ray contrast media; barium sulfate with suspending agents

United States - English - NLM (National Library of Medicine)

vizumax diagnostics llc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - ndications & usage: para uso como agente de contraste en estudios radiográficos.these highlights do not include all the information needed to use, see full prescribing information for, initial u.s. approval.

Australia - English - Department of Health (Therapeutic Goods Administration)

mci aust pty ltd - barium sulfate, quantity: 22 mg/ml - enema - excipient ingredients: sodium polymetaphosphate; carmellose sodium; aluminium magnesium silicate; sodium citrate dihydrate; sorbic acid; docusate sodium; sorbitol solution (70 per cent) (non-crystallising); saccharin sodium; simethicone; sodium methyl hydroxybenzoate; sodium propyl hydroxybenzoate; sodium butyl hydroxybenzoate; phosphoric acid; purified water; flavour - radiological diagnostic aid.

Australia - English - Department of Health (Therapeutic Goods Administration)

mci aust pty ltd - barium sulfate, quantity: 1250 mg/ml - liquid, multipurpose - excipient ingredients: sodium citrate dihydrate; sodium polymetaphosphate; phosphoric acid; sorbic acid; saccharin sodium; carmellose sodium; docusate sodium; purified water; aluminium magnesium silicate; sorbitol solution (70 per cent) (non-crystallising); flavour; dimeticone 100; peg-4 stearate; glyceryl distearate; peg-3 distearate; peg-20 stearate; simethicone; sodium methyl hydroxybenzoate; sodium ethyl hydroxybenzoate; sodium propyl hydroxybenzoate - evidence not provided by sponsor.

United States - English - NLM (National Library of Medicine)

cardinal health - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block and myocardial damage.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. parenteral administration of the drug is contraindi